-
Published 9/1/2026
Brannagan TH, Weiler M, Cruz MW, Khella S, Berk JL, Gertz M, Masri A, Maurer MS, Wixner J, Nåtman J, Kwoh TJ, Pola M, Obici L. Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO-TTRansform Clinical Trial. J Peripher Nerv Syst. 2026 Sep; 31(3):e70167. PMID: 42697856.
-
Published 7/9/2026
Sekijima Y, Ueda M, Berk JL, Obici L, Witteles RM, Planté-Bordeneuve V, Weiler M, Fontana M, Cruz MW, Coelho T, Ericzon BG, Garcia-Pavia P, Beirão J, Wixner J, Lobato L, Ando Y, Merlini G, Maurer MS. Guidelines for the management of hereditary ATTR amyloidosis 2026. Amyloid. 2026 Sep; 33(3):247-272. PMID: 42423415.
-
Published 6/3/2026
Berk JL, Carroll KJ, Mejia Baranda J, Pilebro B, Samuelsson K, Eldhagen P, Wixner J. Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experience. Amyloid. 2026 Jun 03; 1-7. PMID: 42233236.
-
Published 5/1/2026
Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, Gillmore JD, Grodin JL, Mitchell JD, Mooney D, Nativi-Nicolau J, Poulsen SH, Ruberg FL, Chen C, Ji A, Siddhanti S, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Maurer MS, Cheng RK. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876. PMID: 42128580.
-
Published 4/15/2026
Sanchorawala V, Greatsinger A, Staron A, Berk JL, Mendelson LM, Joshi T, J Burke N, Tabatabaeepour N, Smith J, Signorovitch J. Disease burden of ATTR amyloidosis based on the SF-36® health survey. Cardiooncology. 2026 Apr 15; 12(1). PMID: 41987333.